Literature DB >> 8541160

Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction.

E Arbustini1, M Grasso, R Fasani, C Klersy, M Diegoli, E Porcu, N Banchieri, P Fortina, C Danesino, G Specchia.   

Abstract

OBJECTIVE: To investigate the association of the three angiotensin converting enzyme (ACE) genotypes, DD, ID, and II, with the occurrence or absence of coronary atherosclerosis and with myocardial infarction and hypertension.
DESIGN: Cohort analysis study.
SETTING: North-Italy reference centre.
SUBJECTS: 388 white Italian patients (281 males; mean age 60.7 (SD 12.5) years) with proven coronary atherosclerosis (n = 255) or with angiographically normal coronary arteries (n = 133). A further group of 290 healthy blood donors was tested for allele frequency comparison.
INTERVENTIONS: ACE/ID polymorphism was analysed with polymerase chain reaction on DNA from white blood cells. MAIN OUTCOME MEASURES: Coronary atherosclerosis, myocardial infarction, hypertension.
RESULTS: The D and I allele frequencies were respectively 0.63 and 0.37 in the overall healthy blood donor group and 0.66 and 0.34 in the overall study group. In the latter, univariate analysis showed (1) that coronary atherosclerosis (255 patients) was associated with the deletion allele, with an odds ratio (OR) of 5.78 for DD/II, P < 0.001, and 2.39 for ID/II, P = 0.006; and (2) that myocardial infarction (154 patients) was associated with the DD genotype (OR DD/II = 2.56, P = 0.007), but not with the ID genotype (OR DD/II = 1.96, P = 0.056). Finally, hypertension proved to be unrelated with the ACE genotype. The distribution between the three genotypes of known risk factors for coronary artery disease was similar. Logistic regression modelling, performed to test the association of the selected risk factors simultaneously with coronary atherosclerosis and myocardial infarction, showed that the deletion allele (whether DD or ID) was the strongest risk factor for atherosclerosis, and that the D allele was significantly associated with the risk of infarction (although to a lesser extent than with coronary atherosclerosis).
CONCLUSION: ACE deletion polymorphism is strongly and independently associated with coronary atherosclerosis and, to a lesser extent, with myocardial infarction. As such, the results are analogous to what has already been reported in French white, Japanese, and Welsh coronary patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541160      PMCID: PMC484110          DOI: 10.1136/hrt.74.6.584

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  32 in total

1.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

2.  Atherosclerotic lesions in humans. In situ immunophenotypic analysis suggesting an immune mediated response.

Authors:  A C van der Wal; P K Das; D Bentz van de Berg; C M van der Loos; A E Becker
Journal:  Lab Invest       Date:  1989-08       Impact factor: 5.662

3.  Inflammation and the onset of myocardial infarction.

Authors:  D H Spodick
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

4.  Distribution of plasma angiotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters.

Authors:  F Alhenc-Gelas; J Richard; D Courbon; J M Warnet; P Corvol
Journal:  J Lab Clin Med       Date:  1991-01

5.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

6.  Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension.

Authors:  S Dux; N Aron; G Boner; A Carmel; A Yaron; J B Rosenfeld
Journal:  Isr J Med Sci       Date:  1984-12

7.  The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension.

Authors:  I F Islim; D G Beevers; D Bareford
Journal:  J Hypertens       Date:  1992-04       Impact factor: 4.844

8.  Family history of myocardial infarction as an independent risk factor for coronary heart disease.

Authors:  Y Friedlander; J D Kark; Y Stein
Journal:  Br Heart J       Date:  1985-04

9.  Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.

Authors:  L Tiret; B Rigat; S Visvikis; C Breda; P Corvol; F Cambien; F Soubrier
Journal:  Am J Hum Genet       Date:  1992-07       Impact factor: 11.025

10.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

View more
  12 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  Angiotensin-converting enzyme deletion allele is beneficial for the longevity of Europeans.

Authors:  Matea Zajc Petranović; Tatjana Skarić-Jurić; Nina Smolej Narančić; Zeljka Tomas; Petra Krajačić; Jasna Miličić; Maja Barbalić; Spomenka Tomek-Roksandić
Journal:  Age (Dordr)       Date:  2011-05-26

Review 3.  Genes and the development of vascular disease.

Authors:  C A Foy; P J Grant
Journal:  Postgrad Med J       Date:  1997-05       Impact factor: 2.401

4.  Increased risk for ischaemic events is related to combined RAS polymorphism.

Authors:  P P van Geel; Y M Pinto; A H Zwinderman; R H Henning; A J van Boven; J W Jukema; A V Bruschke; J J Kastelein; W H van Gilst
Journal:  Heart       Date:  2001-04       Impact factor: 5.994

5.  Association of Angiotensin converting enzyme gene insertion / deletion polymorphism with risk of ischemic heart disease in a population of smokers in southern India.

Authors:  Sandhya Metta; Satyanarayana Uppala; Doddamani R Basalingappa; Srinivasa R Badeti; Geeta Mitta; Shruti Mohanty; Poornima Subhadra; Qurratulain Hasan
Journal:  J Clin Diagn Res       Date:  2015-04-01

6.  C677T methylentetrahydrofulate reductase and angiotensin converting enzyme gene polymorphisms in patients with Alzheimer's disease in Iranian population.

Authors:  Mohammad Reza Keikhaee; Susan Bany Hashemi; Hossein Najmabadi; Maryam Noroozian
Journal:  Neurochem Res       Date:  2006-08-12       Impact factor: 3.996

7.  Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention.

Authors:  M Hamon; S Fradin; A Denizet; E Filippi-Codaccioni; G Grollier; R Morello
Journal:  Heart       Date:  2003-03       Impact factor: 5.994

8.  Gender specificity of a genetic variant of angiotensin-converting enzyme and risk of coronary artery disease.

Authors:  Negar Firouzabadi; Nader Tajik; Ehsan Bahramali; Hooman Bakhshandeh; Mohsen Maadani; Massoumeh Shafiei
Journal:  Mol Biol Rep       Date:  2013-05-10       Impact factor: 2.316

9.  ACE polymorphism and use of ACE inhibitors: effects on memory performance.

Authors:  Jaqueline B Schuch; Pamela C Constantin; Vanessa K da Silva; Camila Korb; Daiani P Bamberg; Tatiane J da Rocha; Marilu Fiegenbaum; Alcyr de Oliveira; Luciana A Tisser; Fabiana M de Andrade
Journal:  Age (Dordr)       Date:  2014-04-04

Review 10.  Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?

Authors:  Naoki Yamamoto; Rain Yamamoto; Yasuo Ariumi; Masashi Mizokami; Kunitada Shimotohno; Hiroshi Yoshikura
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.